ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although ~80% of newly diagnosed chronic-phase CML patients receiving imatinib acquire complete cytogenetic response, imatinib resistance is inevitable in ~40% of patients attributed to BCR-ABL kinase domain mutations [6].